TECX
NASDAQ HealthcareTectonic Therapeutic, Inc. - Common Stock
Biotechnology
Tectonic Therapeutic, Inc., a biotechnology company, focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G protein coupled receptors (GPCRs). It develops GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines. The company's lead product is TX45, a Fc-relaxin fusion molecule that activates the RXFP1 receptor, the GPCR target of the hormone, and relaxin. It is also developing TX2100 for the treatment of hereditary hemorrhagic telangiectasia; GPCR modulator bispecific for treating fibrosis; and other GPCR modulators. The company is headquartered in Watertown, Massachusetts.
�� 市场数据
| 价格 | $30.65 |
|---|---|
| 成交量 | 162,808 |
| 市值 | 578.34M |
| 贝塔系数 | 0.100 |
| RSI（14日） | 49.1 |
| 200日均线 | $24.62 |
| 50日均线 | $30.57 |
| 52周最高 | $39.53 |
| 52周最低 | $14.39 |
| Forward P/E | -6.55 |
| Price / Book | 2.50 |
🎯 投资策略评分
TECX 在各投资策略中的评分。分数越高，越符合该策略目标。
🔍 策略解读
最佳匹配： 💰 Dividend Daddy (51/100) — 此策略 高股息率 + 低波动性.
评分最低的策略： 🐋 Institutional Whale (14/100). 单一评分不构成买入或卖出信号 — 请结合多种视角综合判断。 了解如何解读这些评分 →
📚 了解更多
在文本中查找 TECX in your text
粘贴任何文章、记录或帖子 — 工具将提取 TECX 以及每一个其他隐藏的股票代码。
免责声明：本数据仅供教育和娱乐用途，不构成金融建议。市场数据可能存在延迟。在做出投资决策之前，请始终进行自己的研究。
数据最后更新： 2026-07-16.